Skip to main content
    V

    Vertex Pharmaceuticals Inc (VRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $534.20
    -3.59 (-0.67%)

    Market Cap: $136.35B

    Last updated: Nov 17, 2026 at 4:39 PM ET

    Vertex Pharmaceuticals Inc (VRTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Vertex Pharmaceuticals (VRTX) has a market cap of $136.35B and an enterprise value of $135.87B. It kept 30.70% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 0.35% below the market cap, as cash exceeds debt.

    Market Cap$136.35B
    Enterprise Value$135.87B
    Latest price (Nov 17, 2026)$534.20

    Key Dates

    The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 10, 2027 (expected)
    Last Earnings DateNov 2, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.08% in the quarter ended Sep 30, 2026 and shrank 0.88% a year over 2 years.

    Shares Outstanding253.50M
    Shares Change (YoY)-0.82%
    Shares Change (QoQ)-0.08%
    Share Count Growth (2Y CAGR)-0.88%

    Valuation Ratios

    Sales and book value multiples are 10.5x and 6.5x. Its year-end P/E ranged from 16.9x to 87.7x from 2016 to 2025.

    P/E Ratio29.8x
    Forward P/E28.7x
    P/S Ratio10.5x
    Forward P/S10.3x
    P/B Ratio6.5x
    P/TBV Ratio13.6x
    P/FCF Ratio42.3x
    P/OCF Ratio36.9x
    PEG Ratio2.2

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 29.6x EBITDA and 42.1x free cash flow.

    EV / Earnings34.2x
    EV / Sales10.5x
    EV / EBITDA29.6x
    EV / FCF42.1x

    Price Statistics

    The stock is up 22.20% over 52 weeks and trades 2.28% above its 50-day average.

    Beta (1Y)0.43
    52-Week Change+22.20%
    1-Month Change+6.42%
    3-Month Change-3.24%
    6-Month Change+23.00%
    5-Year Change+202.21%
    10-Year Change+636.73%
    Total Return (1Y)+22.20%
    Total Return (3Y CAGR)+15.08%
    Total Return (5Y CAGR)+23.59%
    Return vs SPY (1Y)+11.10%
    Max Drawdown (1Y)-15.21%
    Max Drawdown (3Y)-29.07%
    Sharpe Ratio (1Y)0.70
    Correlation with SPY (1Y)0.20
    50-Day Average$522.31
    200-Day Average$483.99
    52-Week Range$412.27 to $568.67
    RSI (14 Days)50.4
    Average Volume (20 Days)1.56M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.34x current liabilities, and total debt is 0.22x shareholder equity.

    Current Ratio2.34x
    Quick Ratio1.89x
    Debt / Equity0.22x
    Debt / EBITDA0.99x
    Debt / FCF1.40x
    Interest Coverage313.20x

    Returns and Efficiency

    Return on invested capital is 14.22% over the last 12 months, against a 5-year average of 19.00%.

    Return on Equity (ROE)19.02%
    Return on Assets (ROA)12.15%
    Return on Invested Capital (ROIC)14.22%
    ROE (5Y Average)17.11%
    ROA (5Y Average)12.94%
    ROIC (5Y Average)19.00%
    Asset Turnover0.45x
    Inventory Turnover0.93x
    Receivables Turnover5.83x
    Cash Conversion Cycle365 days

    Taxes

    Income tax took 16.46% of pretax income over the last 12 months.

    Income Tax (TTM)$783.20M
    Effective Tax Rate16.46%

    Scores

    VRTX has an Altman Z-Score of 8.64, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score8.64
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $12.95B over the last 12 months is up 10.48% from the 12 months before.

    Revenue$12.95B
    Revenue Growth (YoY)+10.48%
    Gross Profit$11.08B
    Operating Income$4.30B
    Pretax Income$4.76B
    Net Income$3.98B
    Reported EPS (TTM)$17.91

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 63.87% of the $32.74B in total assets.

    Cash and Equivalents$4.98B
    Total Debt$4.50B
    Net Cash$482.70M
    Net Cash Per Share$1.90
    Working Capital$6.69B
    Shareholder Equity$20.91B
    Book Value Per Share$82.47
    Tangible Book Value$9.97B
    Tangible Book Per Share$39.31
    Total Assets$32.74B
    Total Liabilities$11.83B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $492.30M of capital spending, operating cash flow left $3.20B of free cash flow.

    Operating Cash Flow$3.69B
    Capital Expenditures$492.30M
    Free Cash Flow$3.20B
    FCF Per Share$12.63
    Depreciation and Amortization$237.30M
    Share Repurchases$1.06B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 33.23%, against a 5-year average of 31.29%.

    Gross Margin85.53%
    Operating Margin33.23%
    Pretax Margin36.75%
    Net Margin30.70%
    FCF Margin24.73%
    Gross Margin (5Y Average)87.11%
    Operating Margin (5Y Average)31.29%
    Net Margin (5Y Average)26.57%

    Growth

    Revenue grew 10.35% a year over 3 years, and EPS 7.33% a year.

    Revenue Growth (3Y CAGR)+10.35%
    Revenue Growth (5Y CAGR)+14.10%
    EPS Growth (3Y CAGR)+7.33%
    EPS Growth (5Y CAGR)+12.27%
    FCF Growth (3Y CAGR)-6.64%
    FCF Growth (5Y CAGR)+1.30%
    Operating Income Growth (3Y CAGR)-1.05%
    Book Value Per Share Growth (2Y CAGR)+4.00%
    Tangible Book Per Share Growth (2Y CAGR)+5.66%

    Revenue and profit by year

    Dividends and Yields

    VRTX does not pay a dividend. Its free cash flow yield is 2.36%.

    Earnings Yield3.36%
    FCF Yield2.36%
    Buyback Yield0.67%
    Shareholder Yield0.67%

    Stock Splits

    The last split was a 2-for-1 forward split on Aug 24, 2000.

    Last Split DateAug 24, 2000
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 5 similar companies, VRTX has the 4th highest P/E.

    P/E Ratio29.8x vs 33.2x median
    P/S Ratio10.5x vs 15.9x median
    ROIC14.22% vs -28.89% median
    Revenue Growth (Trailing 4 Quarters, YoY)+10.48% vs +15.86% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 10.50% and EPS growth at 4.01% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+10.50%
    EPS Growth Forecast (2Y CAGR)+4.01%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About VRTX

    What is VRTX's market cap?

    Vertex Pharmaceuticals has a market cap of $136.35B. Its enterprise value, which adds debt and subtracts cash, is $135.87B.

    What is VRTX's P/E ratio?

    Vertex Pharmaceuticals has a trailing P/E ratio of 29.8x and a forward P/E of 28.7x.

    How many shares of VRTX are outstanding?

    Vertex Pharmaceuticals has 253.50M shares outstanding. The count is down 0.82% from a year earlier.

    Does VRTX pay a dividend?

    No. Vertex Pharmaceuticals does not pay a dividend.

    How much debt does VRTX have?

    Vertex Pharmaceuticals has $4.50B of total debt and $4.98B of cash and equivalents, a net cash position of $482.70M.